Skip to Content

Posts tagged with "Alzheimer’s Disease"

  • Alzheimer's Disease

    Alzheimer’s Markers and Collaboration

    I’m of two minds on this New York Times article on Alzheimer’s research. It details some recent progress on biomarkers for the disease, and that work does look to be useful. A lot of people have proposed diagnostics and markers for Alzheimer’s and its progression over the years, but none of them have really panned… Read More
  • Alzheimer's Disease

    Alzheimer’s and Amyloid, Again

    I wanted to mention this good article in the New York Times on the amyloid hypothesis and Alzheimer’s. That’s a topic I’ve covered often here, but this is a good overview of the field. And it’s a good overview of the field’s big questions, too: is amyloid really the cause of Alzheimer’s? Do we have… Read More
  • Alzheimer's Disease

    Alzheimer’s: Extracting Data From Failed Trials

    It’s no secret that Alzheimer’s disease has been a disastrous area in which to do drug discovery. Every large drug company has had failures in the area, and many smaller ones have gone out of business trying their hands. (I had several years in the field myself earlier in my career, trying three different approaches… Read More
  • Aging and Lifespan

    The Memory Goes Because. . .the Acetyl Groups Go?

    I’ve been meaning to write about this paper from a recent issue of Science. They’ve been studying the differences between young (3-month) mice and old (16-month) mice – their ability to learn, and to remember. Markers of neuronal plasticity and the like are pretty similar between the groups, although the older mice definitely show… Read More
  • Alzheimer's Disease

    A Brief and Not At All Intemperate Evaluation of the Current Literature

    In keeping with my Modest Literature Proposal from earlier this year, I would like to briefly point out a Journal of Medicinal Chemistry paper on potential Alzheimer’s therapies. Whose lead compound has a nine-carbon alkyl chain in the middle of it. And weighs 491. And has two quaternary nitrogens. Which structural features will, in all… Read More
  • Aging and Lifespan

    Rapamycin for Alzheimer’s?

    Last summer a paper was published (PDF) showing rapamycin dosing appeared to lengthen lifespan in mice. (In that second link, I went more into the background of rapamycin and TOR signaling, for those who are interested). Now comes word that it also seems to prevent cognitive deficits in a mouse model of Alzheimer’s. The PDAPP… Read More
  • Alzheimer's Disease

    Beta-Amyloid: An Antibiotic?

    Now here’s something that I don’t think anyone expected. A recent paper in PLoS One makes the case that beta-amyloid, the protein that has been fingered for decades as a major player in Alzheimer’s disease, is actually part of the body’s antimicrobial defenses. Well, it’s good to hear that it’s doing something. M… Read More
  • Alzheimer's Disease

    Dimebon, Grasping at Straws

    Robert Langreth, an editor at Forbes, points to a possible way that Dimebon could get approval for Alzheimer’s: for its behavioral effects, not anything to do with amyloid or memory. I’m not buying it, I have to say. Even Langreth’s source admits that behavioral numbers didn’t reach statistical significance. I don’t se… Read More
  • Alzheimer's Disease

    Dimebon Comes Crashing to Earth

    Earlier this month I wrote about Medivation and their Russian-derived clinical candidate for Alzheimer’s disease, Dimebon (latrepirdine). At the time, I wrote that “A lot of eye-catching numbers from small Phase II trials tend to flatten out in the wider world of Phase III, and if forced, that’s the way I’d bet here.”… Read More
  • Alzheimer's Disease

    A Modest Literature Proposal

    Looking through the latest papers to show up in the Journal of Medicinal Chemistry, this one on BACE-1 inhibitor compounds caught my eye. Perhaps I’m about to be unfair to it. At any rate, I’m going to ask of it something it doesn’t provide: data in something that’s alive. Doesn’t have to be a person… Read More
...91011...